The Technical Analyst
Second Sight Medical [EYES]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Medical - Devices
Second Sight Medical Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.05% $4.14
/ 31 aug 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 210.05 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Jul 04, 2022 |
| SharesOutstanding: | 50.74 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2022-08-30 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.01 - 4.27 ( +/- 3.21%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-08-30 | Mendelsohn Adam | Sell | 0 | Common Stock |
| 2022-08-30 | Le Truc | Sell | 0 | Common Stock |
| 2022-08-30 | Makes Brigid | Sell | 0 | Common Stock |
| 2022-08-30 | Dwyer Donald | Sell | 0 | Common Stock |
| 2022-08-30 | Porter Lisa Ellen | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 99 transactions |
| Buy: 1 980 853 | Sell: 270 010 |
Forecast:
01:40 - $2.91
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.14 (-5.05% ) |
| Volume | 0.0358 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EYES
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EYES
As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
Last 10 Buy Signals
Latest Press Releases
2021-08-11 06:00:00 - Press Release
Second Sight Medical Products Announces A New Nih Grant Supplement For Its Orion Study
Los angeles--(business wire)--second sight medical products, inc. (nasdaq: eyes) (the “company” or “second sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the company received a grant supplement from the national institutes of health (nih) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprosthese
2021-06-25 13:39:00 - Press Release
Second Sight Medical Products Announces Closing Of Public Offering
Los angeles--(business wire)--second sight medical products, inc. (nasdaq: eyes) (“second sight” or the “company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underw
2021-06-22 20:59:00 - Press Release
Second Sight Medical Products Announces Pricing Of Public Offering
Los angeles--(business wire)--second sight medical products, inc. (nasdaq: eyes) (“second sight” or the “company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions an
2021-06-22 16:39:00 - Press Release
Second Sight Medical Products Announces Proposed Public Offering Of Common Stock
Los angeles--(business wire)--second sight medical products, inc. (nasdaq: eyes) (“second sight” or the “company”) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. all of the shares of common stock are to be sold by the company. the offering is subject to market conditions and there can be no a
2021-05-13 06:00:00 - Press Release
Second Sight Medical Products Announces Year Three Nih Funding Of Its Orion Study
Los angeles--(business wire)--second sight medical products, inc. (nasdaq: eyes) (the “company” or “second sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the company received notice from the national institutes of health (nih) of the release of year three funding for its early feasibility clinical trial of a visual cortical prosthesis (the orion trial), grant uh3ns103442.
Latest News
2022-08-19 07:10:14 - Pulse2
Second Sight Medical Products (EYES) Stock: 1-For-3 Split Goes Into Effect
A 1-for-3 reverse split of Second Sight Medical Products (EYES) has gone into effect. These are the details.
2022-02-08 09:15:04 - PennyStocks
Trading Penny Stocks? Top Stock Market News For February 8th, 2022
What you need to know about trading penny stocks on February 8th The post Trading Penny Stocks? Top Stock Market News For February 8th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-02-08 06:33:09 - Benzinga
Second Sight Medical To Merge With AstraZeneca-Backed Nano Precision Medical
Second Sight Medical Products Inc (NASDAQ: EYES) will acquire privately-held Nano Precision Medical Inc in an all-stock transaction. Second Sight Medical develops implantable visual prosthetics.
2021-08-11 06:00:00 - Business Wire
Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study
LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprosthese
2021-07-22 12:34:59 - PennyStocks
Highest Volume Penny Stocks to Watch Today? Check These 4 Out
Best high-volume penny stocks for your watchlist right now? Check these 4 out The post Highest Volume Penny Stocks to Watch Today?
2021-07-22 09:41:11 - InvestorPlace
EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight
EYES stock is set for another day of double-digit gains after the European patent agency approved the company's application. The post EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight appeared first on InvestorPlace.
2021-07-22 07:43:26 - Pulse2
EYES Stock Increases Over 15% Pre-Market: Why It Happened
The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by over 15% pre-market. This is why it happened.
2021-07-06 14:35:58 - PennyStocks
Top Biotech Penny Stocks to Buy This Week? 9 To Watch
Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?
2021-06-30 13:32:00 - PennyStocks
Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now
Current & former penny stocks to watch if you like biotech right now. The post Best Penny Stocks For Your July 2021 List?
2021-06-25 13:39:00 - Business Wire
Second Sight Medical Products Announces Closing of Public Offering
LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underw